Document is current
Any future updates will be listed below
-
Authors
Jasra, Sakshi
Giricz, Orsi https://orcid.org/0000-0002-1328-3682
Zeig-Owens, Rachel
Pradhan, Kith
Goldfarb, David G.
Barreto-Galvez, Angelica
Silver, Alexander J. https://orcid.org/0000-0001-8255-3140
Chen, Jiahao
Sahu, Srabani
Gordon-Mitchell, Shanisha
Choudhary, Gaurav S.
Aluri, Srinivas
Bhagat, Tushar D.
Shastri, Aditi
Bejan, Cosmin A.
Stockton, Shannon S.
Spaulding, Travis P.
Thiruthuvanathan, Victor
Goto, Hiroki
Gerhardt, Jeannine
Haider, Syed Hissam
Veerappan, Arul https://orcid.org/0000-0002-6617-5335
Bartenstein, Matthias
Nwankwo, George
Landgren, Ola https://orcid.org/0000-0001-6485-4839
Weiden, Michael D.
Lekostaj, Jacqueline
Bender, Ryan
Fletcher, Frederick
Greenberger, Lee
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Steidl, Ulrich
Will, Britta https://orcid.org/0000-0002-9534-6690
Nolan, Anna https://orcid.org/0000-0002-0631-1171
Madireddy, Advaitha https://orcid.org/0000-0002-4730-5325
Savona, Michael R. https://orcid.org/0000-0003-3763-5504
Prezant, David J.
Verma, Amit https://orcid.org/0000-0001-7592-7693
- License Information
-
More Information
Article History
Received: 27 August 2019
Accepted: 19 January 2022
First Online: 7 March 2022
Competing interests
: A.V. has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly, is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene, receives honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. M.R.S has acted as a scientific advisor for Abbvie, BMS, CTI, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda, TG Therapeutics; has received research funding from ALX Oncology, Astex, Incyte, Takeda, TG Therapeutics; and has equity positions in Karyopharm, Ryvu.
